In January 2022, the McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies and Mindset announced a collaboration that will support the development of psychedelic medicines. MSRD made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset.
In March 2021, Mindset entered a co-development agreement with InterVivo Solutions Inc. (“InterVivo“), to co-develop a new translational testing platform that Mindset and InterVivo expect will introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. The program will focus on establishing both pharmacological and pharmacokinetics data sets using sophisticated behavioural assays as well as state-of-the art in vivo sampling and analytical techniques.
In November 2020, Mindset entered into a secured convertible promissory note transaction with the OBI. OBI is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. OBI’s collaborative ‘team science’ approach promotes brain research, commercialization and care by connecting researchers, clinicians, industry, patients, and their advocates to improve the lives of those living with brain disorders.
